Naoto Ueno MD PhD (He/Him)

Breast Cancer

University of Hawaiʻi Cancer Center Director Professor of Medicine

701 Ilalo Street, Room 622Honolulu, HI 96813
Phone+1 808-586-3013

Dr. Ueno is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ueno's full profile Already have an account?

Summary

Dr. Naoto Ueno is an academic oncology specialist based in Honolulu, HI, with a subspecialty in breast cancer, particularly experienced in managing various types, including inflammatory, triple-negative, and metastatic breast cancer. He completed his fellowship in Medical Oncology at the University of Texas MD Anderson Cancer Center at Houston and earned a PhD in Cancer Biology at UT GSBS. Dr. Ueno holds the title of Director at the University of Hawaiʻi Cancer Center and is a staff physician at Hawaii Pacific Health and Queenʻs Health System. His previous role was as a Professor of Medicine at The University of Texas MD Anderson Cancer Center. Anderson Cancer Center. He is actively involved in clinical trials focused on innovative treatments for breast cancer and has contributed to numerous publications, with his research addressing mechanisms of drug resistance and racial disparities in breast cancer outcomes. He has been recognized with honors, including the CMS Meaningful Use Stage 1 Certification and the Regents’ Outstanding Teaching Award.

Education & Training

UT Graduate School of Biomedical SciencePhD, Cancer Biology, 1994 - 1999
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1993 - 1996
UPMC Medical EducationResidency, Internal Medicine, 1990 - 1993
OtherClass of 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

HI State Medical License 2022 - 2028
TX State Medical License 1993 - 2026
FL State Medical License 2021 - 2023
OK State Medical License 2020 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Regents’ Outstanding Teaching Award The University of Texas System, 2013

Clinical Trials

Herceptin and GM-CSF for Metastatic Breast Cancer
COMPLETED
PHASE2
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer Start of enrollment: 2007 Apr 17
RECRUITING
Roles: Contact, Principal Investigator
Denosumab for Breast Cancer With Bone Mets Start of enrollment: 2015 Feb 09
TERMINATED
PHASE2

Publications & Presentations

PubMed

Multiscale modeling uncovers macrophage infiltration and TNF-α signaling networks for targeting in inflammatory breast cancer tumor emboli.
Pritha Pai, Christophe Van Berckelaer, Steven Van Laere, Alexandra Bennion, Theresa Charity
Breast. 2026-08-01
ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.
Xuemei Xie, Jangsoon Lee, Young Jin Gi, Thanasis Poullikkas, Jon A Fuson
British Journal of Cancer. 2026-07-01
Reprogramming the Immune Landscape of Inflammatory Breast Cancer.
Verena Martinez-Rodriguez, Suguru Ogata, Xiaoping Wang, Naoto T Ueno
Advanced Science. 2026-06-01

Journal Articles

Rates of Immune Cell Infiltration in Patients with Triple-Negative Breast Cancer by Molecular Subtype
Wendy A Woodward, Naoto T Ueno, Savitri Krishnamurthy, Bora Lim, PLoS One
Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer
Michael C Stauder, Anthony Lucci, Wendy A Woodward, Bora Lim, Naoto T Ueno, ScienceDirect

Lectures

Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Eicosapentaenoic Acid in Combination with EPHA2 Inhibition Shows Efficacy in Preclinical Models of Triple-Negative Breast Cancer by Disrupting Cellular Cholesterol EffluxNovember 2018
Eicosapentaenoic Acid in Combination with EPHA2 Inhibition Shows Efficacy in Preclinical Models of Triple-Negative Breast Cancer by Disrupting Cellular Cholesterol EffluxNovember 2018
Eicosapentaenoic Acid in Combination with EPHA2 Inhibition Shows Efficacy in Preclinical Models of Triple-Negative Breast Cancer by Disrupting Cellular Cholesterol EffluxNovember 2018

Press Mentions

Social Media in Oncology: Was the Prediction Right?July 29th, 2026
University of Hawai’i Cancer Center Opens Hawaiʻi’s First Early-Phase Cancer Clinical Research CenterJuly 7th, 2026
This 25-Year-Old Survived Breast Cancer. Now, She's Dealing with MenopauseJuly 31st, 2025

Grant Support

CD44 splice variants as novel antibody-targets for advanced breast cancerUNIVERSITY OF TEXAS AT AUSTIN2026–2031
University of Hawaii Cancer Center CCSGUNIVERSITY OF HAWAII AT MANOA1997–2029
Developing a novel combination immunotherapy for triple-negative breast cancerUNIVERSITY OF HAWAII AT MANOA2023–2028
Validation of a novel 3D culture platform for TNBC treatment selectionMETHODIST HOSPITAL RESEARCH INSTITUTE2022–2027
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancerUNIVERSITY OF HAWAII AT MANOA2022–2027